docetaxel and capecitabine

DRUG3 trials

Sponsors

Oncology Specialties, Alabama, European Organisation for Research and Treatment of Cancer - EORTC, University of Turku

Conditions

Breast CancerMetastatic Breast CancerStomach Neoplasms

Phase 2

Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

TerminatedNCT00225056

Oncology Specialties, AlabamaMetastatic Breast Cancer

Start: 2003-10-31End: 2006-11-30Target: 43Updated: 2007-04-20

Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer

University of TurkuStomach Neoplasms

Start: 2006-06-30Target: 50Updated: 2008-04-30

Phase 3

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

CompletedNCT00433589

European Organisation for Research and Treatment of Cancer - EORTCBreast Cancer

Start: 2007-02-28End: 2020-03-31Target: 6600Updated: 2022-11-17

Related Papers

Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers

npj Breast Cancer2024-11-022 citations

Abstract P5-14-01: Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial

Cancer Research2023-03-01

Abstract PD4-06: PD4-06 Obesity-associated changes in transcriptomic profile and immune landscape of primary breast cancer revealed by bulk and single-cell gene expression data

Cancer Research2023-03-01

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

2021-03-12234 citations

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

Journal of Clinical Oncology2020-05-2063 citations

Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.

Journal of Clinical Oncology2017-05-204 citations

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.

2017-04-203 citations

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

New England Journal of Medicine2016-08-241961 citations

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

2014-04-0148 citations